ArticleLa Radiologia medica2021
Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Article in La Radiologia medica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Integrin-binding sialoprotein as an extracellular matrix-associated independent prognostic biomarker in glioma.BMC cancer · 2026Article
- Advanced Neuroimaging and Emerging Systemic Therapies in Glioblastoma: Current Evidence and Future Directions.Biomedicines · 2025Review
- Bevacizumab in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
- Quantitative MRI in Neuroimaging: A Review of Techniques, Biomarkers, and Emerging Clinical Applications.Brain sciences · 2025Review
- TRK Inhibitors in Adult and Pediatric High-Grade Gliomas: A Systematic Review and Individual Participant Data Meta-Analysis.Cancers · 2025Review
- Real-world adverse event profile and signal characteristics of bevacizumab in glioma: a FAERS-based disproportionality analysis.Frontiers in pharmacology · 2025Article
- Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma.Frontiers in oncology · 2025Article
- Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study.Frontiers in oncology · 2025Article
- Treatment mechanism and research progress of bevacizumab for glioblastoma.American journal of cancer research · 2025Review
- Spinal and cervical nodal metastases in a patient with glioblastoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Clinical features and treatment of apoplectic intratumoral hemorrhage of glioma.BMC neurology · 2024Article
- Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.Cancer management and research · 2024Article
- Article
- Artificial intelligence and radiation effects on brain tissue in glioblastoma patient: preliminary data using a quantitative tool.La Radiologia medica · 2023Article
- Article
- Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas.Acta neurochirurgica · 2023Article
- Percutanous Electrochemotherapy (ECT) in Primary and Secondary Liver Malignancies: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Glioblastoma Treatment: State-of-the-Art and Future Perspectives.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-grade gliomas are among the most aggressive central nervous system primary tumors, with a high risk of recurrence and a poor prognosis. Re-operation, re-irradiation, chemotherapy are options in this setting. No-best therapy has been established. Bevacizumab was approved on the basis of two Phase 2 trials that evaluated its efficacy in patients with recurrent glioblastoma. MATERIALS AND
methodsWe have retrospectively review data of patients with high-grade glioma treated at our institution that undergone radiological or histological progression after at least one systemic treatment for recurrent disease. Bevacizumab was administered alone or in combination with chemotherapy until disease progression or unacceptable toxicity. Bevacizumab regimen was analyzed to assess PFS and OS. Histological, molecular and clinical features of the entire cohort were collected.
resultsWe reviewed data from 92 patients, treated from April 2009 to November 2019, with histologically confirmed diagnosis of high-grade gliomas and recurrent disease. A PFS of 55.2%, 22.9% and 9.6% was observed at 6, 12 and 24 months, respectively. Performance status, age at diagnosis (< 65 or > 65 ys.) and use of corticosteroids during bevacizumab therapy were strongly associated with PFS. The OS was 74.9% at 6 months, 31.7% at 12 months, 10.1% at 24 months. In our cohort, 51.1% were long-term responders (PFS > 6 months). Globally, bevacizumab treatment was well tolerated.
conclusionOur analysis confirms the efficacy of bevacizumab in recurrent high-grade glioma patients with an acceptable toxicity profile, in keeping with its known safety in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.